Sensus Healthcare (SRTS) Expected to Announce Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS) is expected to be releasing its earnings data after the market closes on Wednesday, February 5th. Analysts expect Sensus Healthcare to post earnings of $0.10 per share and revenue of $10.31 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Sensus Healthcare Trading Up 19.8 %

NASDAQ:SRTS opened at $8.23 on Monday. The stock has a 50 day simple moving average of $7.50 and a 200 day simple moving average of $6.84. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33. The stock has a market cap of $134.89 million, a P/E ratio of 14.44 and a beta of 1.21.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SRTS. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a research report on Friday. They issued a “buy” rating and a $18.00 target price for the company. Maxim Group boosted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, HC Wainwright raised their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, November 18th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.